Veronica Steri, PhD
Specialist
HDF Comprehensive Cancer Ctr
School of Medicine

I am an experienced Research Scientist skilled in Preclinical Tumor Models and in vivo Imaging. I received my education in Italy (Master Degree in Biotechnology) and UK (PhD in Biomolecular Science). After post-doctoral training at UCSF, I joined the UCSF Preclinical Therapeutics core in 2018 and I have been appointed PTC Manager in 2021. In this role, I run a lab that conducts preclinical oncology trials for UCSF Comprehensive Cancer Center investigators.

Awards

Show all (3) Hide

• Travel Fellowship Award, EACR, 2013
• Honor Fell / Company of Biologists Travel Awards, BSCB, 2012
• Unipharma-Graduates Project 3, Sapienza University (Rome), 2007

Education & Training

Show all (4) Hide

• PhD Tumor Angiogenesis UEA 2015
• Habilitation Biology Alma Mater Studiorum 2008
• Master Medical Biotechnology Alma Mater Studiorum 2007
• Bachelor Biotechnology Alma Mater Studiorum 2004

Publications (33)

Top publication keywords:
Integrin alphaVbeta3Receptor, ErbB-3Leukemia, Myeloid, AcuteEndothelium, VascularProto-Oncogene Proteins p21(ras)Tissue FixationIntegrin beta3Camelids, New WorldReceptor, ErbB-2Neoplasms, ExperimentalEndothelial CellsCarcinogenesisAntigens, Differentiation, B-LymphocyteNeovascularization, PathologicCytodiagnosis

• Chemoproteomics reveals immunogenic and tumor-associated cell surface substrates of ectokinase CK2α.
  bioRxiv : the preprint server for biology 2024 Delaveris CS, Kong S, Glasgow J, Loudermilk RP, Kirkemo LL, Zhao F, Salangsang F, Phojanakong P, Camara Serrano JA, Steri V, Wells JA
• Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
  bioRxiv : the preprint server for biology 2024 Kasap C, Izgutdina A, Patiño-Escobar B, Kang A, Chilakapati N, Akagi N, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Wicaksono G, …
• CD46-targeted theranostics for Positron Emission Tomography and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y,…
• Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.
  Journal for immunotherapy of cancer 2023 Temple WC, Nix MA, Naik A, Izgutdina A, Huang BJ, Wicaksono G, Phojanakong P, Serrano JAC, Young EP, Ramos E, Salangsang F, Steri V, Xirenayi S, Hermiston M, Logan AC, Stieglitz E, Wiita AP
• Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML.
  Cell reports. Medicine 2023 Popescu B, Stahlhut C, Tarver TC, Wishner S, Lee BJ, Peretz CAC, Luck C, Phojanakong P, Camara Serrano JA, Hongo H, Rivera JM, Xirenayi S, Chukinas JA, Steri V, Tasian SK, Stieglitz E, Smith CC

Show all (28 more) Hide

• Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target.
  Nature cancer 2023 Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano …
• Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
  Cancer research 2023 Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, …
• Comparison and calibration of dose delivered by137Cs and x-ray irradiators in mice.
  Physics in medicine and biology 2022 Caravaca J, Peter R, Yang J, Gunther C, Antonio Camara Serrano J, Nostrand C, Steri V, Seo Y
• Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins.
  Nature biotechnology 2022 Pance K, Gramespacher JA, Byrnes JR, Salangsang F, Serrano JC, Cotton AD, Steri V, Wells JA
• A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy.
  Cancer cell 2022 Zhang Z, Rohweder PJ, Ongpipattanakul C, Basu K, Bohn MF, Dugan EJ, Steri V, Hann B, Shokat KM, Craik CS
• Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.
  Cell reports 2022 Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM
• Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
  Cell chemical biology 2022 Ferguson ID, Lin YT, Lam C, Shao H, Tharp KM, Hale M, Kasap C, Mariano MC, Kishishita A, Patiño Escobar B, Mandal K, Steri V, Wang D, Phojanakong P, Tuomivaara ST, Hann B, Driessen C, Van Ness B, …
• Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.
  The Journal of clinical investigation 2022 Lim SA, Zhou J, Martinko AJ, Wang YH, Filippova EV, Steri V, Wang D, Remesh SG, Liu J, Hann B, Kossiakoff AA, Evans MJ, Leung KK, Wells JA
• Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.
  Cell reports 2022 Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM
• Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.
  Cell reports 2022 Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM
• Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1.
  Oncogene 2022 Melnyk JE, Steri V, Nguyen HG, Hwang YC, Gordan JD, Hann B, Feng FY, Shokat KM
• The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.
  Scientific reports 2021 Majumder A, Sandhu M, Banerji D, Steri V, Olshen A, Moasser MM
• Surface Proteomics Reveals CD72 as a Target for In Vitro-Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL.
  Cancer discovery 2021 Nix MA, Mandal K, Geng H, Paranjape N, Lin YT, Rivera JM, Marcoulis M, White KL, Whitman JD, Bapat SP, Parker KR, Ramirez J, Deucher A, Phojanokong P, Steri V, Fattahi F, Hann BC, Satpathy AT, Manglik…
• Transit-Amplifying Cells Coordinate Changes in Intestinal Epithelial Cell-Type Composition.
  Developmental cell 2021 Sanman LE, Chen IW, Bieber JM, Steri V, Trentesaux C, Hann B, Klein OD, Wu LF, Altschuler SJ
• The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells.
  Bioorganic & medicinal chemistry 2020 Melnyk JE, Steri V, Nguyen HG, Hann B, Feng FY, Shokat KM
• Systematic identification of engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation.
  Proceedings of the National Academy of Sciences of the United States of America 2020 Elledge SK, Tran HL, Christian AH, Steri V, Hann B, Toste FD, Chang CJ, Wells JA
• KRASG12C inhibition produces a driver-limited state revealing collateral dependencies.
  Science signaling 2019 Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR, Choi ALM, Mitchell DC, Swaney DL, Hann B, Gordan JD, Shokat KM, Gilbert LA
• HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
  Cancer research 2018 Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM
• Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules.
  The Journal of pathology 2018 He B, Jabouille A, Steri V, Johansson-Percival A, Michael IP, Kotamraju VR, Junckerstorff R, Nowak AK, Hamzah J, Lee G, Bergers G, Ganss R
• Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
  Science translational medicine 2017 Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G
• Antagonizing Integrin β3 Increases Immunosuppression in Cancer.
  Cancer research 2016 Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, Fox GC, Kobayashi T, Steri V, Roomp K, Fontana F, Hurchla MA, Knolhoff BL, Meyer MA, Morgan EA, Tomasson JC, Novack JS, Zou W, Faccio R, Novack DV, …
• Suppression of β3-integrin in mice triggers a neuropilin-1-dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis.
  Disease models & mechanisms 2015 Ellison TS, Atkinson SJ, Steri V, Kirkup BM, Preedy ME, Johnson RT, Ruhrberg C, Edwards DR, Schneider JG, Weilbaecher K, Robinson SD
• Redefining the role(s) of endothelial αvβ3-integrin in angiogenesis.
  Biochemical Society transactions 2014 Atkinson SJ, Ellison TS, Steri V, Gould E, Robinson SD
• Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice.
  Circulation research 2013 Steri V, Ellison TS, Gontarczyk AM, Weilbaecher K, Schneider JG, Edwards D, Fruttiger M, Hodivala-Dilke KM, Robinson SD
• Fast track biopsy method: a rapid approach to preoperative diagnoses.
  Pathologica 2010 Steri V, Farnedi A, Montinari E, Foschini MP
• Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain.
  Science (New York, N.Y.) 2008 Faure-André G, Vargas P, Yuseff MI, Heuzé M, Diaz J, Lankar D, Steri V, Manry J, Hugues S, Vascotto F, Boulanger J, Raposo G, Bono MR, Rosemblatt M, Piel M, Lennon-Duménil AM
• Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets.
  Blood 2007 Piccioli D, Tavarini S, Borgogni E, Steri V, Nuti S, Sammicheli C, Bardelli M, Montagna D, Locatelli F, Wack A
• AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1245
  Abstract 1245: RRx-001 is effective in temozolomide-sensitive and resistant GBM. Steri V., Oronsky B., Scicinski J, Bergers B.